China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary

China's Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $1.46 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.6% from 2022 to 2030 and will reach $2.84 Bn in 2030. In China, millions of people suffer from the common and dangerous respiratory condition known as a chronic obstructive pulmonary disease (COPD). Due to the increased prevalence of COPD and growing awareness of the condition, the COPD treatment market in China is anticipated to expand significantly over the next few years. Bronchodilators, corticosteroids, and combination therapy are the most frequently utilized COPD treatments in China.

In China, bronchodilators are the most often used COPD medication, and it is anticipated that they will hold this position throughout the prediction period. In addition to conventional medications, alternative therapies including acupuncture and herbal treatments are gaining popularity in China for the treatment of COPD. The demand for these complementary therapies is anticipated to increase as a result of the Chinese government's promotion of traditional Chinese medicine (TCM) as a treatment for COPD.

Market Dynamics

Market Growth Drivers

The prevalence of COPD in China is on the rise due to factors such as air pollution and smoking. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the prevalence of COPD in China is estimated to be around 13.7%, which translates to approximately 99 Mn people. This growing prevalence of COPD is expected to drive the demand for COPD treatments in China. The elderly population in China is also growing rapidly, which is expected to increase the demand for COPD treatments. According to a report by the National Bureau of Statistics of China, the population aged 65 and above in China reached 190.64 Mn in 2020, accounting for 13.5% of the total population. This demographic trend is expected to boost the demand for COPD treatments, as the disease is more common in elderly individuals.

The Chinese government has been taking steps to improve the treatment of COPD and other respiratory diseases. For example, the government has launched several initiatives to improve air quality and reduce air pollution, which is a major risk factor for COPD. The government has also been promoting traditional Chinese medicine as a complementary treatment for COPD. These initiatives are expected to drive the demand for COPD treatments in China. There is also a growing awareness of COPD among the Chinese population, which is expected to increase the demand for COPD treatments. For example, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has been actively promoting COPD awareness in China through campaigns and educational programs. This is expected to increase the number of patients seeking treatment for COPD in China.

Market Restraints

The cost of COPD treatment in China can be a significant barrier to access for many patients. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the cost of COPD treatment in China can range from $1,000 to $2,600 USD) per year. This high cost can limit access to treatment for many patients, particularly those in rural areas or with low incomes. China's healthcare system is facing challenges in meeting the growing demand for COPD treatment. According to a report by the China Health Statistical Yearbook, there were 1.55 doctors per 1,000 population in China in 2020, which is lower than in many other countries. This shortage of healthcare resources can limit access to COPD treatment, particularly in rural areas. Many patients in China may not be aware of the symptoms of COPD or the importance of seeking treatment. According to a study published in the Journal of Thoracic Disease, there is a lack of public awareness of COPD in China, with only 16.4% of respondents in a survey indicating that they had heard of the disease. This lack of patient education can result in delayed diagnosis and treatment, which can worsen the outcomes of COPD. While there are several COPD treatments available in China, some newer treatments may not be widely available.

Competitive Landscape

Key Players

• SinoPharm Group
• Hutchison China MediTech
• Zhejiang Hisun Pharmaceutical
• Haisco Pharmaceutical Group
• Shanghai Sine Promod Pharmaceutical
• AstraZeneca
• Boehringer Ingelheim Pharmaceuticals
• Novartis
• Pfizer
• Teva China Limited

Healthcare Policies and Regulatory Landscape

Healthcare policy is a critical aspect of any healthcare system, and China is no exception. The Chinese government has implemented several healthcare policies in recent years to address various challenges in the healthcare system, including those related to COPD treatment. Some of the key healthcare policies in China that impact COPD treatment include:

In 2016, the Chinese government launched the Healthy China 2030 initiative, which aims to improve the health and well-being of the Chinese population. The initiative includes several goals related to respiratory health, including reducing the incidence of COPD and improving the treatment of the disease.

The National Essential Medicines List (NEML) is a list of essential medicines that are recommended for use in the Chinese healthcare system. The NEML includes several COPD treatments, including bronchodilators and corticosteroids, which are available at lower prices to patients.

The Chinese government has been promoting traditional Chinese medicine (TCM) as a complementary treatment for COPD. In 2018, the government issued guidelines for the diagnosis and treatment of COPD with TCM, which included several TCM treatments for the disease. China has been implementing healthcare reform measures aimed at improving the accessibility and affordability of healthcare services. For example, the government has expanded health insurance coverage to more of the population and has increased funding for rural healthcare services.

Reimbursement Scenario

Reimbursement is a critical aspect of healthcare, as it helps patients access necessary treatments and medications. In China, the reimbursement scenario for COPD treatment is complex, with different reimbursement policies and systems in place for different types of treatments. Some key aspects of the reimbursement scenario for COPD treatment in China include:

China's Basic Medical Insurance system is the primary source of healthcare coverage for many Chinese citizens. Under this system, COPD treatments that are included in the National Essential Medicines List (NEML) are covered by insurance. However, the amount of coverage varies depending on the type of treatment and the insurance policy.

This insurance program is available to urban employees and their dependents. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy. This insurance program is available to urban residents who do not have access to the Urban Employee Basic Medical Insurance program. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy. This insurance program is available to rural residents. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy.